Toxicities of Novel Agents for the Treatment of Advanced Bladder Cancer.
Eur Urol Focus
; 10(2): 222-223, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38851928
ABSTRACT
Enfortumab vedotin and erdafitinib have specific toxicities that need careful management in order to optimise drug exposure while maintaining patients' quality of life. Patient education, meticulous monitoring, and a multidisciplinary approach are key to optimising outcomes so that patients can reap the benefits of these new treatments.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pirazóis
/
Neoplasias da Bexiga Urinária
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article